The World Privacy Forum filed extensive comments with the US Department of Health and Human Services about its proposed changes regarding the rules governing human subject medical research. In the comments, WPF noted that the HHS approach to privacy for research subjects was incomplete and did not use all Fair Information Practices. WPF strongly urged HHS to revise its proposal on a number of issues, including consent and the use of biospecimens in research. The World Privacy Forum is urging HHS to acknowledge that the realm of health data that is truly non-identifiable has shrunken remarkably, for example, biospecimens with DNA cannot be considered non-identifiable anymore. “In our comments, we are requesting that HHS give individuals the opportunity to make choices about the use of their own health data and specimens,” said Executive director Pam Dixon. WPF also stated in its comments that “A central database with identifiable information about participants in human subjects research is a terrible idea.” (See p. 21 of WPF comments.)
World Privacy Forum information and materials on medical identity theft.
The World Privacy Forum today filed its comments on the proposed changes to the HIPAA privacy rule, supporting some proposed changes and suggesting additional changes to enhance patient choice. In particular, the WPF supports the new patient right to an access report that has been added (p. 4), and has requested that Health Information Exchanges also be required to provide accountings of disclosures to patients (p. 18). The WPF generally argued that HHS needs to look forward and allow changes in information technology to fully benefit patients by providing the facility for more accounting rather than less (pp. 2-3). If the HIPAA rule gives patients a greater ability to monitor how their information is used and disclosed, patients will pay attention and requests for accounting of disclosures will become more common.
The World Privacy Forum filed comments with the Federal Trade Commission regarding its consent decree against Ceridian regarding a substantial data breach. WPF has requested that the Commission present more facts in the case to the public, and has also requested more clarity about the FTC complaint process, noting that it is not a transparent process for the public.
Consumers receive breach letters — Pharmaceutical manufacturer GSK, maker of drugs Paxil, Boniva, Advair, and many others, sent a letter to consumers who had registered on one or more of its product websites. Due to the Epsilon data breach, registrants’ names, email, and the product they registered for was breached. Information people give to a company via a pharmaceutical product web site such as this is not usually covered under HIPAA. See our Patient’s Guide to HIPAA for more on what is covered under HIPAA and what is not. WPF recommends that consumers use a “throwaway” or temporary email address if deciding to register at a Pharmaceutical product web sites.